Timed sampling is essential because pharmacokinetic parameters depend on how concentrations change, not on a single measurement. Samples collected at defined intervals from plasma, blood, urine, or another biological matrix create a concentration–time profile. Analytical assays quantify the drug in each sample, while subsequent analysis converts the profile into estimates such as exposure, clearance, and half-life.
Analytical and computational stages answer different questions. Chromatographic analysis and mass spectrometry determine how much drug is present in a biological sample, whereas compartmental or noncompartmental modeling interprets the resulting measurements. Keeping these roles distinct helps researchers separate measurement uncertainty from conclusions about disposition, including bioavailability, volume of distribution, clearance, and elimination over time.
Compartmental and noncompartmental modeling provide complementary ways to interpret concentration–time data. Both can support characterization of drug exposure and disposition, but they represent different computational approaches rather than additional laboratory assays. Including either approach after concentration measurement allows pharmacologists to translate observed drug levels into parameters used to compare formulations or dosing conditions.
An analysis generally proceeds from study sampling to quantitative assay and then to modeling. Investigators collect biological specimens at planned time points, measure drug concentrations with an appropriate analytical method, organize the results as concentration–time data, and estimate pharmacokinetic parameters. This sequence links each numerical estimate to both the sampling schedule and the assay results.
Pharmacokinetic Measurement Methods are especially useful when a development or dosing decision depends on drug exposure over time. In formulation development, the measurements help characterize how a formulation behaves; in dose selection, they support comparison of exposure-related parameters. The same workflow can also be applied in drug interaction studies, where concentration profiles help examine altered disposition.
In clinical practice, concentration measurements can support therapeutic monitoring by showing drug levels in relation to time and treatment. In research, the resulting parameters contribute to evaluation of safety and efficacy, while clearance, half-life, bioavailability, and volume of distribution provide distinct descriptions of disposition. Together, these outputs give complementary information for interpreting drug exposure in pharmacology.